MIM
SRPT icon

MetLife Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

MetLife Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
60,707
+55,372
+1,038% +$1.05M ﹤0.01% 1485
2026
Q1 		$116K Buy
5,335
+97
+2% +$1.88K ﹤0.01% 2474
2025
Q4 		$113K Buy
5,238
+38
+0.7% +$801 ﹤0.01% 2551
2025
Q3 		$100K Sell
5,200
-51,140
-91% -$912K ﹤0.01% 2650
2025
Q2 		$963K Sell
56,340
-614
-1% -$26.2K 0.01% 1336
2025
Q1 		$3.63M Sell
56,954
-795
-1% -$83.7K 0.02% 771
2024
Q4 		$7.02M Buy
57,749
+4,422
+8% +$542K 0.04% 391
2024
Q3 		$6.66M Sell
53,327
-575
-1% -$79.5K 0.04% 388
2024
Q2 		$8.52M Buy
53,902
+48,462
+891% +$6.23M 0.05% 284
2024
Q1 		$704K Buy
5,440
+17
+0.3% +$2.08K ﹤0.01% 1496
2023
Q4 		$523K Sell
5,423
-74
-1% -$7.1K ﹤0.01% 1661
2023
Q3 		$666K Buy
5,497
+2
+0% +$226 0.01% 1460
2023
Q2 		$629K Buy
5,495
+396
+8% +$51.1K ﹤0.01% 1549
2023
Q1 		$703K Buy
5,099
+12
+0.2% +$1.56K 0.01% 1433
2022
Q4 		$659K Sell
5,087
-133
-3% -$15.4K 0.01% 1470
2022
Q3 		$577K Buy
5,220
+3
+0.1% +$302 ﹤0.01% 1531
2022
Q2 		$391K Sell
5,217
-172
-3% -$12.7K ﹤0.01% 1835
2022
Q1 		$421K Buy
+5,389
New +$413K ﹤0.01% 1877
2019
Q2 		– Sell
-273
Closed -$32.7K – 2579
2019
Q1 		$32.7K Buy
273
+182
+200% +$23.4K ﹤0.01% 2388
2018
Q4 		$9.93K Buy
91
+4
+5% +$500 ﹤0.01% 2377
2018
Q3 		$14.1K Buy
+87
New +$11.9K ﹤0.01% 2407
2018
Q2 		– Sell
-27,646
Closed -$2.05M – 2221
2018
Q1 		$2.05M Hold
27,646
– – 0.02% 770
2017
Q4 		$1.54M Buy
+27,646
New +$1.46M 0.02% 864

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MetLife Investment Management's SRPT Position: Q2 2026 in Review

MetLife Investment Management increased its Sarepta Therapeutics (SRPT) stake by 1,038% in Q2 2026, buying an estimated $1.05M and bringing the position to 60,707 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

MetLife Investment Management first reported a position in SRPT in Q4 2017 and has held it in 23 quarters since. The position peaked at $8.52M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • MetLife Investment Management held 60,707 shares of Sarepta Therapeutics worth $1.09M as of Q2 2026.
  • MetLife Investment Management bought 55,372 Sarepta Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Sarepta Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1485 holding.
  • MetLife Investment Management first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • MetLife Investment Management's Sarepta Therapeutics position peaked at $8.52M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.